Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2021-05-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients who present to clinic or in the outpatient setting with worsening heart failure represent a unique opportunity for novel approaches to decongestion (removing fluid) that may more rapidly improve fluid status and symptoms as well as reduce the risk of hospitalization.

In these patients with less severe congestion (fluid overload), combining the vasopressin antagonist tolvaptan with loop diuretics (or fluid pills like furosemide/bumetanide/torsemide) may represent a more effective strategy for decongestion. In addition, looking at patients' copeptin levels may help identify those who are more likely to respond to tolvaptan.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Tolvaptan in Healthy Adults

NCT01973140

Healthy

COMPLETED PHASE4

Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management

NCT01584557

Heart Failure

COMPLETED PHASE3

Efficacy and Safety of Tolvaptan in Japanese Patients With Acute Heart Failure

NCT01635517

Heart Failure

COMPLETED

Tolvaptan for Advanced or Refractory Heart Failure

NCT02959411

Heart Failure Hyponatremia

TERMINATED PHASE4

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

NCT00094302

Cardiovascular Diseases Heart Diseases Heart Failure, Congestive

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a randomized, double blind, positive control, multi-center clinical trial enrolling patients who present in the outpatient setting with signs and symptoms consistent with worsening congestive heart failure. The sample size for the study is 40 patients. Candidates for the study will be identified by screening outpatients presenting with worsening heart failure.

Patients who qualify for the study will be enrolled within 24 hours of identification. Patients will be randomized in a 1:1 fashion to one of two treatment arms:

* Augmentation of current daily dose of oral loop diuretic + 30 mg of oral Tolvaptan daily
* Augmentation of current daily dose of oral loop diuretic + placebo of oral Tolvaptan daily

Patients will initiate study medication in a hospital setting and will be observed for a period of time that will depend upon their baseline serum sodium and response to study drug. In most cases patients will be observed for 8 hours. Following this observational period, patients will leave the hospital setting and the remainder of the study will consist of follow-up by outpatient visits or by telephone. All patients will have Day 30 follow up phone contact for assessment of vital status, adverse events and morbidity during this period.

The primary objective of this study will be to compare the effects of oral tolvaptan plus augmented loop diuretic versus augmented loop diuretic on short term changes in body weight with and without stratification for baseline copeptin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tolvaptan

Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily

Group Type EXPERIMENTAL

tolvaptan

Intervention Type DRUG

Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.

Placebo

Augmentation of current dose of loop diuretic

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo for tolvaptan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tolvaptan

Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.

Intervention Type DRUG

Placebo

Placebo for tolvaptan

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Samsca

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years of age
* Presenting to clinic with worsening heart failure due congestion (fluid overload) Patient reported worsening fluid overload based on perception of edema and/or weight gain With at least one of the following symptoms

* Worsening dyspnea on exertion or fatigue
* Worsening orthopnea or paroxysmal nocturnal dyspnea (PND)
* Perception of abdominal and/or lower extremity edema
* Early satiety and/or decreased appetite And at least one of the following signs
* Lower extremity edema
* Ascites
* Elevated jugular venous distension (JVD)
* Pulmonary rales
* Daily oral dose of loop diuretic
* Prior history of heart failure with this diagnosis for at least 1 month with preserved or reduced left ventricular ejection fraction
* Signed informed consent

Exclusion Criteria

* Patients with symptomatic hyponatremia will be excluded from the study.
* Patients with severe hyponatremia, defined as serum sodium \< 125 milliequivalents per Liter (mEq/L) at the time of screening, will be excluded regardless of whether they are symptomatic or not.
* Patients with the following predisposing factors for osmotic demyelinating syndrome (ODS), assessed by the study investigator judgment, will be excluded: chronic alcoholism at the time of study, severe liver disease, marked malnutrition, and risk for chronic hypoxia.
* Patients currently undergoing renal replacement therapy
* Planned hospitalization for acute heart failure
* History of primary significant liver disease or acute hepatic failure, as defined by the investigator
* Hemodynamically significant arrhythmias
* Acute coronary syndrome (ACS) or acute myocardial infarction within 4 weeks prior to study entry
* Active myocarditis
* Hypertrophic obstructive, restrictive, or constrictive cardiomyopathy
* Severe stenotic valvular disease amendable to surgical treatment
* Complex congenital heart disease
* Constrictive pericarditis
* Clinical evidence of digoxin toxicity
* History of adverse reaction or clinical contraindication to tolvaptan

* Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors
* Inability of patient to sense and/or respond to thirst
* History of hypersensitivity to tolvaptan
* Patient is anuric
* Enrollment or planned enrollment in another randomized clinical trial during the study period
* Pregnant or breast-feeding
* Inability to comply with planned study procedures

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No